Today, Pfizer Oncology has an industry-leading portfolio of 25 approved innovative cancer medicines, including major therapies for metastatic breast cancer, prostate cancer, urothelial carcinoma and haemato-oncological malignancies. Pfizer’s in-line portfolio is focused on four broad, key
Today, Pfizer Oncology has an industry-leading portfolio of 25 approved innovative cancer medicines, including major therapies for metastatic breast cancer, prostate cancer, urothelial carcinoma and haemato-oncological malignancies. Pfizer’s in-line portfolio is focused on four broad, key
Today, Pfizer Oncology has an industry-leading portfolio of 25 approved innovative cancer medicines, including major therapies for metastatic breast cancer, prostate cancer, urothelial carcinoma and haemato-oncological malignancies. Pfizer’s in-line portfolio is focused on four broad, key